Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 5/20 | 0.41 |
| ▸ | PPARA | Q07869 | 5/20 | 0.41 |
| ▸ | PPARD | Q03181 | 4/20 | 0.41 |
| ▸ | TSPO | P30536 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 4/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | LTA4H | P09960 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6076525 | 0.86 | PPARG (0.48) | PPARGPPARAPPARDSMN1; SMN2NPC1 | |
| SCHEMBL6076498 | 0.80 | PPARG (0.49) | PPARGPPARAPPARDL3MBTL1 | |
| SCHEMBL6076738 | 0.79 | PGR (0.49) | PPARGPPARAPPARDHTTFFAR1 | |
| SCHEMBL16456491 | 0.74 | PPARG (0.44) | PPARGPPARAPPARDKDM4EALDH1A1 | |
| SCHEMBL16456500 | 0.72 | PPARA (0.44) | PPARGPPARAPPARDSMN1; SMN2KDM4E | |
| SCHEMBL6075851 | 0.72 | PPARA (0.46) | PPARGPPARAPPARDALDH1A1LTA4H | |
| SCHEMBL6396442 | 0.72 | PPARA (0.48) | PPARGPPARAPPARDSMN1; SMN2NPC1 | |
| SCHEMBL7253863 | 0.71 | PPARG (0.62) | PPARGPPARAPPARD | |
| SCHEMBL7926847 | 0.71 | PPARG (0.62) | PPARGPPARAPPARD | |
| SCHEMBL6076606 | 0.70 | ADORA3 (0.51) | PPARGPPARAPPARDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030236254-A1 | Novel heterocyclic compounds having hypolipidemic, hypocholesteremic activities process for their preparation and pharmaceutical compositions containing them and their use in medicine | CADILA HEALTHCARE LIMITED (IN) | 2003-12-25 | — | — | US | claimed |
| US-7041837-B2 | Heterocyclic compounds having hypolipidemic, hypocholesteremic activities process for their preparation and pharmaceutical compositions containing them and their use in medicine | CADILLA HEALTHCARE LIMITED (IN) | 2006-05-09 | — | — | US | disclosed |
| US-20030236254-A1 | Novel heterocyclic compounds having hypolipidemic, hypocholesteremic activities process for their preparation and pharmaceutical compositions containing them and their use in medicine | CADILA HEALTHCARE LIMITED (IN) | 2003-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236254-A1 | Novel heterocyclic compounds having hypolipidemic, hypocholesteremic activities process for their preparation and pharmaceutical compositions containing them and their use in medicine | LIPA, LIPC, CYP46A1 | PPARG 129/4885PPARA 68/4885PPARD 143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.